Please login to the form below

Not currently logged in
Email:
Password:

Veltassa

This page shows the latest Veltassa news and features for those working in and with pharma, biotech and healthcare.

Evotec and Vifor announce joint venture for kidney disease treatments

Evotec and Vifor announce joint venture for kidney disease treatments

number of treatments including Veltassa, Mircera and Velphoro.

Latest news

  • NICE says no to AZ and Vifor’s rival hyperkalaemia drugs NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

    Vifor’s Veltassa (patiromer) gained US approval in 2015 and in Europe in 2017. ... Denmark. This has given Vifor a head start overall, but Veltassa sales remain modest: it chalked up revenues of 36.8m in the first six months of 2018.

  • Real-world data finds patients feel better on Entresto, says Novartis Real-world data finds patients feel better on Entresto, says Novartis

    Lokelma (sodium zirconium cyclosilicate or ZS-9) and Vifor Pharma’s Veltassa (patiromer) which “will be a particularly valuable addition to the clinic if efficacy can be confirmed in clinical trials”.

  • AZ gets US approval for Veltassa rival Lokelma AZ gets US approval for Veltassa rival Lokelma

    But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia. ... That left AZ playing catch-up in the market with Vifor’s Veltassa (patiromer), which was approved in the US in 2015 and got a European green light last

  • AZ finally gets EU nod for Veltassa rival Lokelma AZ finally gets EU nod for Veltassa rival Lokelma

    challenge Vifor Pharma’s Veltassa (patiromer) which was approved in the EU last year and has been sold in the US since 2015. ... For its part, Vifor has said securing payer coverage for Veltassa in the US has been a little slow, but is gaining momentum

  • Vifor wins European approval for Veltassa Vifor wins European approval for Veltassa

    The go-ahead is a significant milestone for Vifor Pharma Group - who acquired Veltassa from Relypsa - as it marks the drug’s first regulatory approval outside the US. ... Relypsa plans to submit Veltassa applications in other markets worldwide and the

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    The Vifor division, which focuses on treatments for iron deficiency, has gained a fully integrated US operation prior to the spin-out, and a complementary product in Veltassa, a potassium binder ... Veltassa was approved in late 2015 and Relypsa achieved

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Man vs microbe: the fight against antimicrobial resistance
How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
HOW TO TRANSFORM YOUR HEALTHCARE BRAND MARKETING FROM MULTI-CHANNEL TO OMNICHANNEL
In a previous blog, we outlined the role of omnichannel in healthcare and the importance of personalised communications with the suggestion of using modular content to support an omnichannel approach....